Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
NCT00521924 · Merck Sharp & Dohme LLC · PHASE3 · terminated · last registry update 2017-04-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow Enrollment” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-04-11Results posted on the registry: Celltrion, CT-P13 + Remicade (NCT02096861)
- 2018-03-27Phase 3 first posted: Shanghai Biomabs Pharmaceutical Co., Ltd., CMAB008 + MTX (NCT03478111)
- 2018-03-22Results posted on the registry: ICStudy, LLC, Certolizumab pegol + Placebo (NCT02497976)
- 2018-03-20Results posted on the registry: UCB Pharma SA, Belgium, Certolizumab Pegol + Methotrexate (NCT02151851)
- 2018-02-08Results posted on the registry: Herbert Lindsley, MD, Infliximab + Placebo (NCT01144143)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2018-01-12Also stopped (terminated): Milton S. Hershey Medical Center, Cimzia + Mesalamine (NCT01696942)
- 2018-01-08Also stopped (withdrawn): University of Arkansas, a drug against TNF (NCT02729233)
- 2017-12-21Results posted on the registry: Janssen Research & Development, LLC, Placebo + Golimumab (NCT02181673)
- 2017-12-13Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Infliximab + Cyclophosphamide (NCT03371095)
- 2017-11-30Phase 3 first posted: UCB Biopharma S.P.R.L., e-Device (NCT03357471)
- 2017-11-13Results posted on the registry: Janssen Research & Development, LLC, Placebo + Golimumab (NCT02186873)
- 2017-10-13Results posted on the registry: Merck Sharp & Dohme LLC, Golimumab (NCT02092285)
- 2017-10-10Results posted on the registry: Milton S. Hershey Medical Center, Cimzia + Mesalamine (NCT01696942)
- 2017-09-13Results posted on the registry: Nizar Zein, Infliximab + Placebo (NCT00512278)
- 2017-09-12Results posted on the registry: University of California, Los Angeles, Remicade (NCT00948610)
- 2017-09-11Results posted on the registry: Pfizer, PF-06438179 + Infliximab (NCT02222493)
- 2017-09-01Phase 3 first posted: University Ghent, Golimumab (NCT03270501)
- 2017-09-01Results posted on the registry: Sanofi, Sarilumab + Placebo (NCT01217814)
- 2017-09-01Also stopped (terminated): Sanofi, Sarilumab + Placebo (NCT01217814)
- 2017-08-04Results posted on the registry: AbbVie, adalimumab + ABT-122 (NCT02349451)
- 2017-07-18Phase 3 first posted: IRCCS Burlo Garofolo, Thalidomide + Infliximab (NCT03221166)
- 2017-07-02Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), Mesalamine + Infliximab (NCT00514982)
- 2017-06-19Results posted on the registry: AbbVie, ABT-122 (NCT02433340)
- 2017-05-22Phase 3 first posted: Boston Children's Hospital, Vitamin D3 (NCT03162432)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision